EVALUATION OF rs61330082 AND rs2058539 SNPs IN NAMPT GENE FOR THE PATIENTS WITH TYPE 2 DIABETES


Parıltı D. N. , Çelik S. P. , Açık L. , Yalçın M. M. , Yetkin İ. , Yunusov E.

KARABAĞ 2. ULUSLARARASI UYGULAMALI BİLİMLER KONGRESİ, Baku, Azerbaijan, 8 - 10 November 2021, pp.209-216

  • Publication Type: Conference Paper / Full Text
  • City: Baku
  • Country: Azerbaijan
  • Page Numbers: pp.209-216

Abstract

Diabetes mellitus is a very common disease, which is one of the top 10 causes of death at global level. In 2019, the number of deaths due to diabetes was around 4.2 million in the world. The prevalence of diabetes mellitus of the adult population (20-79 years) was 9.3% and the total number of people that have diabetes was 463 million in the world (2019). Type 2 diabetes is the most common type of diabetes, which is approximately 90% of all diabetes. Type 2 diabetes occurs by the complex interaction of genetics, epigenetics, and environmental factors. Nicotinamide phosphoribosyltransferase (NAMPT) gene is a protein coding gene that is associated with diabetes. We aimed to explain the interaction of single-nucleotide polymorphism with Type 2 diabetes by performing PCR-RFLP method on NAMPT gene. We studied with a control group and three different Type 2 diabetes groups, which consist of patients who have macro complication (such as coronary artery disease (CAD), peripheral arterial disease (PAD) and stroke), micro complication (such as nephropathy, neuropathy and retinopathy) and patients without any complications. We used 22 samples for each patient group. After we isolated DNA from blood samples, we performed PCR. Then we used restriction enzyme to digest NAMPT gene at a specific site, which our selected SNPs are located. Thus, we determined that if the individuals have wild type or mutation according to these SNPs and if there is mutation they were evaluated as whether they had homozygous or heterozygous alleles. For rs61330082, the dominant genotype for both macro complication and without complication groups is heterozygous mutation (45.45%) and for micro complication is homozygous wild type (50%). For rs2058539, the dominant genotype for both micro complication and macro complication groups is heterozygous mutation (respectively 77.27% and 63.64%) and for without complication group is homozygous mutation (50%).